OrthoPediatrics (KIDS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst David Turkaly from JMP Securities reiterated a Buy rating on the stock and has a $50.00 price target.
David Turkaly has given his Buy rating due to a combination of factors that highlight OrthoPediatrics’ strong market position and growth potential. The company has demonstrated robust revenue growth, particularly in the U.S. market, where sales increased by 52% year-over-year. This growth is attributed to OrthoPediatrics gaining market share across its pediatric-orthopedic segments.
Management’s confidence in the company’s fundamentals is evident, with a positive outlook for 2025, including expected sales growth and aEBITDA improvements. Strategic moves such as consolidating operations to the U.S. and managing currency risks in South America further emphasize the company’s focus on cash generation and operational efficiency. OrthoPediatrics is also well-positioned to expand its presence in the underserved pediatric-orthopedic market, supporting the Buy rating with a $50 price target based on future revenue projections.